Compare ADMA Biologics Inc (ADMA) vs IQIYI Inc - ADR (IQ) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

iQIYI (IQ) trades at $0.9954, down 1.45% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025 despite $27.29 billion in revenue, with negative profit margins and declining revenue trends. Recent news highlights leadership changes and AI platform expansion, but financial performance remains pressured.

The outlook is mixed: analyst consensus leans bullish with 50% buy ratings, but fundamental weakness and cash flow volatility pose risks. Investment opportunity hinges on AI-driven turnaround execution, while key risks include sustained profitability challenges and competitive pressures in China's streaming market.